Invex Therapeutics (ASX:IXC) Net Current Asset Value : A$0.07 (As of Dec. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Invex Therapeutics Net Current Asset Value?

In calculating the Net Current Asset Value (NCAV), Benjamin Graham means a company's current assets (such as cash, marketable securities, and inventories) minus its total liabilities (including preferred stock, minority interest, and long-term debt).

Invex Therapeutics's net current asset value per share for the quarter that ended in Dec. 2023 was A$0.07.

The historical rank and industry rank for Invex Therapeutics's Net Current Asset Value or its related term are showing as below:

ASX:IXC' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 0.71 Med: 1.63 Max: 4.53
Current: 1.2

During the past 4 years, the highest Price-to-Net-Current-Asset-Value Ratio of Invex Therapeutics was 4.53. The lowest was 0.71. And the median was 1.63.

ASX:IXC's Price-to-Net-Current-Asset-Value is ranked better than
84.81% of 1027 companies
in the Biotechnology industry
Industry Median: 3.88 vs ASX:IXC: 1.20

Invex Therapeutics Net Current Asset Value Historical Data

The historical data trend for Invex Therapeutics's Net Current Asset Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Invex Therapeutics Net Current Asset Value Chart

Invex Therapeutics Annual Data

Trend

Jun20

Jun21

Jun22

Jun23

Net Current Asset Value

0.36

0.43

0.38

0.28

Invex Therapeutics Semi-Annual Data
	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Net Current Asset Value	Get a 7-Day Free Trial				0.41	0.38	0.33	0.28	0.07

Competitive Comparison of Invex Therapeutics's Net Current Asset Value

For the Biotechnology subindustry, Invex Therapeutics's Price-to-Net-Current-Asset-Value, along with its competitors' market caps and Price-to-Net-Current-Asset-Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Invex Therapeutics's Price-to-Net-Current-Asset-Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Invex Therapeutics's Price-to-Net-Current-Asset-Value distribution charts can be found below:

* The bar in red indicates where Invex Therapeutics's Price-to-Net-Current-Asset-Value falls into.

Invex Therapeutics Net Current Asset Value Calculation

Invex Therapeutics's Net Current Asset Value (NCAV) per share for the fiscal year that ended in Jun. 2023 is calculated as

	Net Current Asset Value Per Share		(A: Jun. 2023 )
=	(Total Current Assets	-	Total Liabilities	-	Minority Interest	-	Preferred Stock)	/	Shares Outstanding (EOP)
=	(22.804	-	1.572	-	0	-	0)	/	75.1538
=	0.28

Invex Therapeutics's Net Current Asset Value (NCAV) per share for the quarter that ended in Dec. 2023 is calculated as

	Net Current Asset Value Per Share		(Q: Dec. 2023 )
=	(Total Current Assets	-	Total Liabilities	-	Minority Interest	-	Preferred Stock)	/	Shares Outstanding (EOP)
=	(6.28	-	0.985	-	0	-	0)	/	75.1538
=	0.07

Invex Therapeutics (ASX:IXC) Net Current Asset Value Explanation

Benjamin Graham first discussed net current asset value (NCAV) in the 1934 edition of "Security Analysis", which he coauthored with David Dodd. In the book, (net) current asset value is defined as:" current assets alone, minus all liabilities and claims ahead of the issue."

The common definition of NCAV is: NCAV = current assets – [total liabilities + minority interest + preferred stock]

Net current assets exclude not only the intangible assets but also the fixed and miscellaneous assets. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Grahams strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their Net-Net Working Capital. They are collected under our Net-Net screener.

Invex Therapeutics Net Current Asset Value Related Terms

Thank you for viewing the detailed overview of Invex Therapeutics's Net Current Asset Value provided by GuruFocus.com. Please click on the following links to see related term pages.

Invex Therapeutics (ASX:IXC) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Invex Therapeutics Ltd (ASX:IXC) » Definitions » Net Current Asset Value

Comparable Companies

Traded in Other Exchanges

N/A

Address

38 Rowland Street, Level 1, Subiaco, WA, AUS, 6008

Website

https://www.invextherapeutics.com

Invex Therapeutics Ltd is a biopharmaceutical company, focused on the research and development of Exenatide as a treatment for neurological conditions such as Idiopathic Intracranial Hypertension (IIH), traumatic brain injury, or acute stroke. Its other program under development is Presendin which can be used for disabling headaches and permanent vision loss in females. Geographically, it operates only in Australia.